Schwab Network

11/14/2025

Markets were mixed Friday, with Nvidia (NVDA) rebounding ahead of earnings next week.

Selling pressure plagued the chipmaker for most of the week as traders and investors questioned the sustainability of the A.I. trade, Kevin Green highlighted.

Here's a quick recap:
https://schwabnetwork.com/articles/closing-bell-markets-rebound-from-early-losses-as-nvidia-earnings-loom/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

The S&P 500 closed flat as investors remained cautious ahead of economic data and on concerns about the decreasing probability of the Fed cutting rates in December

11/14/2025

ICI's Shelly Antoniewicz tells Marley Kayden the government could easily release the September jobs data, but October might be trickier.

Here's her forecast for 2025 GDP, rate-cut expectations and how useful the delayed inflation could be.

Shelly Antoniewicz spotlights the economy and consumer, saying the government could probably easily release the September jobs data, but October might be trickier. “The employment picture data is going to be critically important to the Fed’s decision” around rates in December, she stresses. Sh...

11/14/2025

The White House is eyeing tariff rollbacks to tackle one of consumers' biggest frustrations: food prices.

Marley Kayden explains how the administration is pairing broad tariff exemptions with new Latin American trade frameworks to make imported items such as beef, bananas and coffee beans cheaper.

Cattle and coffee futures fell on expectations that lower import costs could allow stores to cut prices.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

Ahead of Alibaba's (BABA) earnings Tuesday, Brendan Ahern of KraneShares tells Sam Vadas that analysts will be keeping an eye on whether cloud computing could "pick up some of the slack" from the "tepid top-line growth due to the core China e-commerce business."

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

Walmart (WMT) CEO Doug McMillon, will step down January 31 and be succeeded by John Furner, president and CEO of the company's U.S. division.

Tom White breaks down why the move comes at a time of strength and as the company implements AI throughout different divisions.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

Tim Bohen, chief technical trainer of "StocksToTrade," says he told investors that they were "crazy to short" Tesla (TSLA).

"Anytime you see a dip, to me, take advantage of bad news," he adds.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Twitter:Organic:2025-11-14

11/14/2025

Appaloosa Management, led by David Tepper, initiated a new stake in AMD during the third quarter, acquiring 950,000 shares.

The position was valued at approximately $153.7 million, which represented 2.08% of the portfolio as of September 30, 2025.

Appaloosa increased its stake in a number of holdings: Whirlpool (WHR) Qualcomm (QCOM), Baidu (BIDU) and Nvidia (NVDA).

Appaloosa also initiated new stakes in Fiserv (FISV), Truist Financial (TFC) and KeyCorp (KEY), and exited its positions in Intel (INTC) and Oracle (ORCL) during the same quarter, according to the 13F filing.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

Kevin Hincks unpacks this week's volatility in the markets and the driving factors, including the decreasing odds of a rate cut at next month's Fed meeting.

Plus, a look at the notable earnings to focus on next week from companies like Nvidia (NVDA), Walmart (WMT) and Home Depot (HD).

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

11/14/2025

Shares of Cidara Therapeutics (CDTX) skyrocketed, nearly doubling on Friday, after Merck (MRK) said it would buy the maker of an experimental flu therapy in a $9.2 billion deal slated to close in the first quarter of 2026.

The move comes as Merck braces for the looming loss of patent exclusivity for the blockbuster cancer drug Keytruda in 2028.

Merck said Cidara’s lead candidate, CD388, is an antiviral agent currently in Phase 3 studies for the prevention of influenza infection in individuals at higher risk of flu complications.

Merck CEO Rob Davis said Cidara’s CD388 "has the potential to be another important driver of growth through the next decade, creating real value for shareholders."

Shares of $CDTX are up roughly 105%, while $MRK is up about a percent.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14

11/14/2025

Under Armour (UAA) and NBA star Steph Curry have officially parted ways, closing a partnership that spanned more than ten years.

The company announced Thursday that the move will allow it to sharpen its focus on its core brand and accelerate development of new basketball products.

Despite the split, Under Armour will release the Curry 13 in February as planned, with additional apparel collections available through next October.

"Under Armour believed in me early in my career and gave me the space to build something much bigger and more impactful than a shoe," Curry said in a statement.

Under Armour noted the separation is not expected to materially impact its consolidated financial results or profitability.

The decision comes as part of the company’s expanded restructuring plan, which now includes an additional $95 million in charges — bringing the total to as much as $255 million.

For more market news, tune into: SchwabNetwork.com/?CID=SM:Facebook:Organic:2025-11-14